Do Patients Understand The Term ‘Median’ In Advertising? US FDA Aims To Find Out
In first Rx advertising research project of 2023, FDA will survey consumers on how they interpret quantitative claims in DTC ads. Lilly questions design of another study examining relative importance of product information, citing FDA comments at tanezumab advisory committee.
You may also be interested in...
Agency’s final guidance on presenting quantitative efficacy and risk information in direct-to-consumer advertisements includes an additional example, which specifies risk should not be characterized in a way that suggests it is not important.
Office of Prescription Drug Promotion’s latest study is assessing consumer and physician responses to prescription drug promotions with claims about patient adherence and preference. It is one of 73 research projects OPDP has undertaken.
National Advertising Division refers Gilead’s challenge of ViiV’s advertisements to the FDA and FTC after ViiV declines to participate in its review. Gilead says the ads claim Dovato is superior to its HIV drug Biktarvy, while ViiV suggests a review would amount to second-guessing the FDA.